Emerging Treatment for High-Risk HER2-Positive Early Breast Cancer — A new therapeutic option for the primary refractory patients 

The DESTINY-Breast11 trial showed a clinically meaningful and statistically significant improvement in pCR, along with an early favourable EFS trend with neoadjuvant T-DXd-THP. Despite the strong scientific rationale, the potential clinical impact in Finland is in the primary refractory patients, says Päivi Auvinen, Cancer Centre of Kuopio University Hospital, Finland.